Anti-HPV-16 E6/E7 TCR

Drug Profile

Anti-HPV-16 E6/E7 TCR

Alternative Names: HPV-16 E6 & E7

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Kite Pharma; National Cancer Institute (USA)
  • Class Antineoplastics; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Human papillomavirus E6 protein inhibitors; Human papillomavirus E7 protein inhibitors; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical cancer; Head and neck cancer

Most Recent Events

  • 22 May 2017 Phase-I clinical trials in Cervical cancer in USA (Parenteral) (Kite Pharma pipeline, May 2017)
  • 22 May 2017 Phase-I clinical trials in Head and neck cancer in USA (Parenteral) (Kite Pharma pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top